A Day in the Life of a Cell Therapy Specialist at Kite, a Gilead Company
A Day in the Life of a Cell Therapy Specialist at Kite, a Gilead Company
5 Questions with Nesha Miller, Director, Supply Chain, Kite Pharma
5 Questions with Nesha Miller, Director, Supply Chain, Kite Pharma November 14, 2023 1. Tell us about your career path leading up to your current role at Kite. I studied [….]
Addimmune Prepares to Go Public, Initiate Phase Ib HIV Trial
The Rockville-based company, an anticipated SPAC merger of American Gene Technologies HIV business and a 10x Capital Venture Acquisition Corp. III, will list on the New York Stock Exchange under the ticker symbol HIV. The company will have a valuation of $500 million. Funds will be used to advance clinical development of Addimmune’s cell therapy for HIV.
5 Questions With Natalie Ferguson, Artist and Creative Marketing Specialist, American Gene Technologies International, Inc.
5 Questions With Natalie Ferguson, Artist and Creative Marketing Specialist, American Gene Technologies International, Inc. 1. What did you want to be when you grow up? How’d you get from [….]
Why the First Clinical Cure for HIV Will Likely be Developed in Maryland
Why the First Clinical Cure for HIV Will Likely be Developed in Maryland By Chris Frew | September 18, 2023 As was true in the 1980s, Maryland’s DNA Valley remains [….]
18 Top Biotech Companies Hiring This Fall (2023)
18 Top Biotech Companies Hiring This Fall (2023) By Chris Frew | September 9, 2023 While the hiring climate in 2023 has been a far change from the boom that [….]
NextCure: A Biomarker Approach to Immuno-Oncology Therapeutics
NextCure is charging toward the end of the year with three immuno-oncology clinical trials and what they feel is a distinctly unique approach to using biomarkers to guide their drug-development process.
Meet Philadelphia’s Greatest Life Science Industry Workplaces for 2023
Ecolab, JNJ and Several Philadelphia companies in the life sciences industry were recognized as one of America’s Greatest Workplaces 2023.
BioFactura Scores $33.5 Million Global Commercialization Deal for Stelara Biosimilar
The licensing deal paves the way for confirmatory Phase III studies that could lead to regulatory approval across the world.
American Gene Technologies Celebrates Phase I Success of Experimental HIV Cell Therapy
American Gene Technologies Celebrates Phase I Success of Experimental HIV Cell Therapy By Alex KeownJune 13, 2023 American Gene Technologies (AGT) is one step closer to making history with a [….]